Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

USA - NASDAQ:ORGO - US68621F1021 - Common Stock

4.66 USD
+0.08 (+1.75%)
Last: 9/22/2025, 12:57:38 PM
Fundamental Rating

4

Taking everything into account, ORGO scores 4 out of 10 in our fundamental rating. ORGO was compared to 538 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ORGO has reported negative net income.
ORGO had a negative operating cash flow in the past year.
ORGO had positive earnings in 4 of the past 5 years.
In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With an excellent Return On Assets value of -3.38%, ORGO belongs to the best of the industry, outperforming 87.73% of the companies in the same industry.
Looking at the Return On Equity, with a value of -4.32%, ORGO belongs to the top of the industry, outperforming 89.96% of the companies in the same industry.
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROIC N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

In the last couple of years the Operating Margin of ORGO has declined.
The Gross Margin of ORGO (74.58%) is better than 82.53% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ORGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.58%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.62 indicates that ORGO is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.62, ORGO is doing good in the industry, outperforming 75.84% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
The Debt to Equity ratio of ORGO (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.62
ROIC/WACCN/A
WACC10.17%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ORGO has a Current Ratio of 3.95. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a Current ratio (3.95) which is in line with its industry peers.
A Quick Ratio of 3.45 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Quick ratio (3.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.95
Quick Ratio 3.45
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -225.00%.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
Looking at the last year, ORGO shows a decrease in Revenue. The Revenue has decreased by -4.20% in the last year.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%

3.2 Future

ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.28% yearly.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 12.92% on average per year.
EPS Next Y-112%
EPS Next 2Y-11.68%
EPS Next 3Y20.28%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ORGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 35.14, ORGO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 90.15% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.86, ORGO is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 35.14
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

89.22% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 160.85
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ORGO's earnings are expected to grow with 20.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.68%
EPS Next 3Y20.28%

More info and screens

0

5. Dividend

5.1 Amount

ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (9/22/2025, 12:57:38 PM)

4.66

+0.08 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners54.13%
Inst Owner Change7.15%
Ins Owners31.29%
Ins Owner Change0.23%
Market Cap591.17M
Analysts85
Price Target8.16 (75.11%)
Short Float %15.11%
Short Ratio13.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-73%
Max EPS beat(2)-73%
EPS beat(4)2
Avg EPS beat(4)278.21%
Min EPS beat(4)-73%
Max EPS beat(4)688.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.3%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)-4.23%
Revenue beat(4)2
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.38%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)6
Avg Revenue beat(16)-0.09%
PT rev (1m)14.29%
PT rev (3m)28%
EPS NQ rev (1m)22.22%
EPS NQ rev (3m)-35.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-130.77%
Revenue NQ rev (1m)1.9%
Revenue NQ rev (3m)-3.64%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 35.14
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.84
EV/EBITDA 160.85
EPS(TTM)-0.05
EYN/A
EPS(NY)0.13
Fwd EY2.85%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.39
BVpS2.85
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.58%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 74.48%
Cap/Sales 3.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.95
Quick Ratio 3.45
Altman-Z 4.62
F-Score3
WACC10.17%
ROIC/WACCN/A
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
EPS Next Y-112%
EPS Next 2Y-11.68%
EPS Next 3Y20.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
EBIT growth 1Y-221.35%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y-140.26%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-297.24%
OCF growth 3Y-38.8%
OCF growth 5YN/A